

4-1-2022

## Implementation of Clinical Practice Guidelines for Hospitalized Patients With COVID-19 in Academic Medical Centers

Amy Chang Berger

Noa Simchoni

Andrew Auerbach

W Michael Brode

Ethan Kuperman

*See next page for additional authors*

Follow this and additional works at: <https://jdc.jefferson.edu/medfp>



Part of the [Public Health Commons](#)

[Let us know how access to this document benefits you](#)

---

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [JeffersonDigitalCommons@jefferson.edu](mailto:JeffersonDigitalCommons@jefferson.edu).

---

**Authors**

Amy Chang Berger, Noa Simchoni, Andrew Auerbach, W Michael Brode, Ethan Kuperman, Katie Raffel, and Alan Kubey

---

# Implementation of Clinical Practice Guidelines for Hospitalized Patients With COVID-19 in Academic Medical Centers

Amy Chang Berger, MD, PhD; Noa Simchoni, MD, PhD; Andrew Auerbach, MD; W. Michael Brode, MD; Ethan Kuperman, MD; Katie Raffel, MD; Alan Kubey, MD; for the HOMERuN COVID-19 Collaborative Group

## Introduction

COVID-19 management has evolved rapidly, creating challenges for implementation. This study was conducted to assess the fidelity with which academic medical centers (AMCs) adopted evidence into practice.

## + Supplemental content


Author affiliations and article information are listed at the end of this article.

## Methods

This survey study was deemed exempt from review and informed consent by the University of California, San Francisco, because it does not involve human participants. Response rates were computed according to the American Association for Public Opinion Research (AAPOR) reporting guideline.

We surveyed members of the Hospital Medicine Reengineering Network (**Figure 1**)<sup>1</sup> from

**Figure 1. Map of Hospitals Participating in the Hospital Medicine Reengineering Network**



UC indicates University of California; UIHC, University of Iowa Hospitals and Clinics; UNC, University of North Carolina; UNM, University of New Mexico; UPMC, University of Pittsburgh Medical Center; UT, University of Texas; and VCU, Virginia Commonwealth University.

**Open Access.** This is an open access article distributed under the terms of the CC-BY License.

December 17, 2020, to February 10, 2021, and compared their institutional recommendations for COVID-19 management with available evidence at that time from pivotal randomized clinical trials (RCTs) (eAppendix in the [Supplement](#)) and guidelines from the National Institutes of Health,<sup>2</sup> Infectious Diseases Society of America,<sup>3</sup> and American Society of Hematology.<sup>4</sup> Data were analyzed from February 10 to March 4, 2021.

## Results

Of 83 hospitals contacted, 52 (63%) responded. Hospitalist leaders involved in the direct care of patients with COVID-19 provided responses. A total of 49 sites (94%) self-identified as AMCs; the remaining 3 sites (6%) identified as AMC-affiliated teaching hospitals. Fifty-one sites (98%) issued internal COVID-19 management guidance. Guidance at 48 sites (94%) was generated by multidisciplinary committees, including infectious disease (47 sites [98%]), infection control (43 sites [90%]), hospital medicine (42 sites [88%]), and critical care (40 sites [83%]). Of 51 sites with internal COVID-19 management guidance, recommendations were disseminated most commonly through email (43 sites [84%]), institutional websites (42 sites [82%]), and integration into the electronic health record as COVID-19-specific order sets (37 sites [73%]) and note templates (33 sites [65%]). The percentage of institutions recommending each studied intervention is shown in **Figure 2**, alongside simplified RCT findings and guidelines. Notable results include 94% to 100% of sites recommending dexamethasone for patients requiring at least 4 L of oxygen, 69% recommending remdesivir for patients receiving mechanical ventilation, 81% recommending dexamethasone for patients requiring 1 to 2 L of oxygen, 67% implementing awake proning, 35% limiting remdesivir use to the “early or viral phase of illness,” and 17% recommending D-dimer-based therapeutic anticoagulation. The proportion of sites recommending each intervention varied from a low of 10% for convalescent plasma for patients without antibodies to 100% for dexamethasone in patients requiring mechanical ventilation.

## Discussion

In this survey study, 3 themes emerged from our analysis. First, translation from evidence to practice guidelines was remarkably complete for interventions supported by aligned national guidelines and high-quality studies. A striking example is the near universal adoption of dexamethasone among patients requiring at least 4 L of supplementary oxygen only 6 to 8 months after the RECOVERY trial demonstrated a survival benefit. The lone exception to this trend was baricitinib; however, new evidence and guidelines were released within 1 week of survey distribution. Practice convergence was also observed when evidence and guidelines aligned against interventions, as seen in the infrequent recommendation of dexamethasone for patients with oxygen saturation greater than 94%, as measured by pulse oximetry. However, clear opportunity for improvement still exists.

Second, institutions favored treatment over not treatment, particularly when guidelines diverged from each other or from the underlying evidence, as exemplified by 69% to 81% of sites recommending remdesivir or dexamethasone, respectively, when evidence or guidelines conflicted. We suspect this finding reflects systemic biases to do something rather than nothing when faced with uncertainty, likely exacerbated by inconsistent definitions of disease severity across studies and guidelines.

Finally, AMCs demonstrated a willingness to innovate across a range of interventions. Novel interventions, such as awake proning, phase-of-illness-restricted remdesivir, and D-dimer-based therapeutic anticoagulation, varied widely with respect to patient selection and procedural specifics, but collectively, and with 17% to 67% of sites recommending 1 or more of such novel interventions, they demonstrate that AMCs were sophisticated consumers of information, willing to bridge

Figure 2. Comparing Academic Medical Centers' Institutional Recommendations to National Guidelines and Randomized Clinical Trial (RCT) Data

<span style="display: inline-block; width: 15px; height: 10px; background-color: #f4a460; border: 1px solid black;"></span> Evidence of benefit <span style="display: inline-block; width: 15px; height: 10px; background-color: #a4a4a4; border: 1px solid black;"></span> Evidence of no benefit <span style="display: inline-block; width: 15px; height: 10px; background-color: #e0e0e0; border: 1px solid black;"></span> No high-quality evidence <span style="display: inline-block; width: 15px; height: 10px; background-color: #c0e0e0; border: 1px solid black;"></span> Guideline supports use <span style="display: inline-block; width: 15px; height: 10px; background-color: #408080; border: 1px solid black;"></span> Guideline opposes use <span style="display: inline-block; width: 15px; height: 10px; background-color: #e0e0e0; border: 1px solid black;"></span> Neither supports nor opposes use								
Intervention	Disease severity	Notable RCTs		Guidelines		Sites recommending intervention, %		
		ACTT-1	Solidarity	IDSA	NIH			
		Moderate illness (SpO <sub>2</sub> > 94%)	No benefit	No benefit	Suggests against		No recommendation	21
		Severe illness requiring 1-6 L NC	Benefit	No benefit	Suggests use		Recommends use	83
Severe illness requiring HFNC or NIPPV	No benefit	Suggests use	Recommends use		86			
Critical illness requiring mechanical ventilation	No benefit	No benefit	Suggests use	Recommends against	69			
Intervention	Disease severity	Notable RCTs RECOVERY		Guidelines		Sites recommending intervention, %		
		No benefit		IDSA	NIH			
		Moderate illness at high risk for progression	No benefit	Suggests against	Recommends against		20	
		Severe illness (SpO <sub>2</sub> <95%) not receiving O <sub>2</sub>		Suggests use	Recommends against		26	
		Severe illness requiring 1-2 L NC	Benefit	Suggests use	Recommends against		81	
		Severe illness requiring 4-6 L NC		Suggests use	Recommends use		94	
Severe illness requiring HFNC or NIPPV	Suggests use	Recommends use		100				
Critical illness requiring mechanical ventilation	Benefit	Recommends use	Recommends use	100				
Intervention	Disease severity	Notable RCTs ACTT-2		Guidelines		Sites recommending intervention, %		
		Benefit		IDSA	NIH			
Baricitinib	Receiving O <sub>2</sub> + steroids contraindicated	Benefit		No recommendation	Recommends use (12/14/20)	25		
Intervention	Disease severity	Notable RCTs		Guidelines		Sites recommending intervention, %		
		PlasmAr	PLACID	IDSA	NIH			
Convalescent plasma	Early or viral phase of infection	Not evaluated	No benefit	Recommends against	No recommendation	18		
	Undetectable or low antibody titer	No benefit	No benefit			10		
Intervention	Disease severity	Notable RCTs REMAP-CAP, ACTIV-4, ATTACC		Guidelines		Sites recommending intervention, %		
		In progress during survey period		ASH	NIH			
Therapeutic anticoagulation	D-dimer over institution threshold	In progress during survey period		Prophylactic dose recommended	Prophylactic dose recommended	17		
Intervention	Disease severity	Notable RCTs		Guidelines NIH		Sites recommending intervention, %		
		In progress as of manuscript preparation		No recommendation				
		Not receiving O <sub>2</sub>	In progress as of manuscript preparation	"Consider a trial" for persistent hypoxemia			43	
1-6 L NC	"Consider a trial" for persistent hypoxemia			53				
Prone	HFNC or NIPPV	In progress as of manuscript preparation		"Consider a trial" for persistent hypoxemia		61		

The percentage of sites recommending use of each clinical intervention for a given patient population, stratified by disease severity, is presented alongside simplified findings from notable RCTs (eAppendix in the Supplement) and guidelines available at the time of the survey from the National Institutes of Health (NIH),<sup>2</sup> Infectious Diseases Society of America (IDSA),<sup>3</sup> and American Society of Hematology (ASH).<sup>4</sup> No published RCTs were available at the time of the survey for anticoagulation or prone. ACTIV-4 indicates Anti-thrombotics for Adults Hospitalized With COVID-19; ACTT, Adaptive COVID-19 Treatment Trial; ATTACC, Antithrombotic Therapy to Ameliorate

Complications of COVID-19; HFNC, high-flow nasal cannula; NC, nasal cannula; NIPPV, noninvasive positive-pressure ventilation; PLACID, Convalescent Plasma in the Management of Moderate COVID-19 in Adults in India; PlasmAr, Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia; RECOVERY, Randomized Evaluation of COVID-19 Therapy; REMAP-CAP, A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia; SpO<sub>2</sub>, oxygen saturation as measured by pulse oximetry.

knowledge gaps with expert opinion. Additional research is needed to understand how AMCs monitor innovation outcomes and deimplement practices when negative evidence emerges.

Limitations of this study include a 37% nonresponse rate, reliance on self-reporting, lack of longitudinal follow-up, and lack of data on actual clinical practice and outcomes. Nonetheless, our findings demonstrate that AMCs were capable of responding nimbly to emerging data and shifting guidelines, although both overtreatment and experimentation were observed where significant uncertainty persisted. While factors unique to the early pandemic likely shaped this performance, we hope some strategies, such as use of focused multidisciplinary teams and novel information sharing tools, can be harnessed to accelerate the translation of evidence to bedside for COVID-19 and beyond.

---

## ARTICLE INFORMATION

**Accepted for Publication:** January 16, 2022.

**Published:** April 4, 2022. doi:[10.1001/jamanetworkopen.2022.5657](https://doi.org/10.1001/jamanetworkopen.2022.5657)

**Open Access:** This is an open access article distributed under the terms of the [CC-BY License](https://creativecommons.org/licenses/by/4.0/). © 2022 Berger AC et al. *JAMA Network Open*.

**Corresponding Author:** Alan A. Kubey, MD, Thomas Jefferson University Hospital, 833 Chestnut St, Ste 701, Philadelphia, PA 19107 ([alan.kubey@jefferson.edu](mailto:alan.kubey@jefferson.edu)).

**Author Affiliations:** Division of Hospital Medicine, Department of Medicine, University of California, San Francisco (Berger, Simchoni, Auerbach); Division of Hospital Medicine, Department of Internal Medicine, Dell Medical School at University of Texas at Austin, Austin (Brode); Division of General Internal Medicine, Department of Internal Medicine, University of Iowa, Iowa City (Kuperman); Division of Hospital Internal Medicine, Department of Internal Medicine, Denver Health, Denver, Colorado (Raffel); Division of Hospital Medicine, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania (Kubey); Division of Hospital Internal Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota (Kubey).

**Author Contributions:** Drs Berger and Kubey had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Berger and Simchoni contributed equally as co-first authors.

*Concept and design:* Berger, Simchoni, Auerbach, Brode, Raffel, Kubey.

*Acquisition, analysis, or interpretation of data:* Berger, Simchoni, Auerbach, Kuperman, Raffel, Kubey.

*Drafting of the manuscript:* Berger, Simchoni, Auerbach, Kubey.

*Critical revision of the manuscript for important intellectual content:* All authors.

*Obtained funding:* Auerbach.

*Administrative, technical, or material support:* Berger, Auerbach, Kubey.

*Supervision:* Auerbach, Raffel, Kubey.

**Conflict of Interest Disclosures:** None reported.

**Funding/Support:** This study was supported by the Gordon and Betty Moore Foundation (grant No. 8856) and Agency for Healthcare Research and Quality (grant No. R01HS027369) for the Hospital Medicine Reengineering Network (HOMERuN) COVID-19 Collaborative.

**Role of the Funder/Sponsor:** The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

## REFERENCES

1. Auerbach AD, Patel MS, Metlay JP, et al. The Hospital Medicine Reengineering Network (HOMERUN): a learning organization focused on improving hospital care. *Acad Med*. 2014;89(3):415-420. doi:[10.1097/ACM.000000000000139](https://doi.org/10.1097/ACM.000000000000139)
2. National Institutes of Health COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. Accessed December 17, 2020. <https://www.covid19treatmentguidelines.nih.gov/>
3. Bhimraj A, Morgan RL, Shumaker AH, et al. IDSA guidelines on the treatment and management of patients with COVID-19. Version 3.5.1. Accessed December 17, 2020. <https://www.idsociety.org/globalassets/idsa/practice-guidelines/covid-19/treatment/idsa-covid-19-gl-tx-and-mgmt-v3.5.0.pdf>

4. Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. *Blood Adv*. 2021;5(3):872-888. doi:[10.1182/bloodadvances.2020003763](https://doi.org/10.1182/bloodadvances.2020003763)

**SUPPLEMENT.****eAppendix.** Pivotal Randomized Clinical Trials